MEDEXUS PHARMACEUTICALS INC (MDP.CA) Stock Fundamental Analysis
Canada - Toronto Stock Exchange - TSX:MDP - CA58410Q2036 - Common Stock
2.91 CAD
-0.04 (-1.36%)
MDP gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 30 industry peers in the Pharmaceuticals industry. Both the profitability and the financial health of MDP get a neutral evaluation. Nothing too spectacular is happening here. MDP has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
MDP had positive earnings in the past year.
In the past year MDP had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: MDP reported negative net income in multiple years.
In multiple years MDP reported negative operating cash flow during the last 5 years.
1.2 Ratios
MDP has a better Return On Assets (0.25%) than 70.00% of its industry peers.
The Return On Equity of MDP (0.73%) is better than 73.33% of its industry peers.
Looking at the Return On Invested Capital, with a value of 5.79%, MDP belongs to the top of the industry, outperforming 83.33% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for MDP is in line with the industry average of 8.46%.
The last Return On Invested Capital (5.79%) for MDP is well below the 3 year average (9.89%), which needs to be investigated, but indicates that MDP had better years and this may not be a problem.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.25% | ||
| ROE | 0.73% | ||
| ROIC | 5.79% |
ROA(3y)0.64%
ROA(5y)-3.83%
ROE(3y)3.01%
ROE(5y)-32.83%
ROIC(3y)9.89%
ROIC(5y)N/A
1.3 Margins
MDP has a better Profit Margin (0.37%) than 70.00% of its industry peers.
Looking at the Operating Margin, with a value of 5.76%, MDP is in the better half of the industry, outperforming 76.67% of the companies in the same industry.
MDP has a better Gross Margin (53.01%) than 83.33% of its industry peers.
In the last couple of years the Gross Margin of MDP has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 5.76% | ||
| PM (TTM) | 0.37% | ||
| GM | 53.01% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.84%
GM growth 5Y-1.43%
2. Health
2.1 Basic Checks
MDP has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
The number of shares outstanding for MDP has been increased compared to 1 year ago.
Compared to 5 years ago, MDP has more shares outstanding
MDP has a better debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of 0.58, we must say that MDP is in the distress zone and has some risk of bankruptcy.
MDP has a better Altman-Z score (0.58) than 63.33% of its industry peers.
The Debt to FCF ratio of MDP is 1.57, which is an excellent value as it means it would take MDP, only 1.57 years of fcf income to pay off all of its debts.
MDP has a better Debt to FCF ratio (1.57) than 90.00% of its industry peers.
A Debt/Equity ratio of 0.00 indicates that MDP is not too dependend on debt financing.
The Debt to Equity ratio of MDP (0.00) is better than 86.67% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 1.57 | ||
| Altman-Z | 0.58 |
ROIC/WACC0.64
WACC9.12%
2.3 Liquidity
MDP has a Current Ratio of 0.83. This is a bad value and indicates that MDP is not financially healthy enough and could expect problems in meeting its short term obligations.
MDP has a Current ratio of 0.83. This is amonst the worse of the industry: MDP underperforms 93.33% of its industry peers.
MDP has a Quick Ratio of 0.83. This is a bad value and indicates that MDP is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Quick ratio value of 0.38, MDP is not doing good in the industry: 90.00% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.83 | ||
| Quick Ratio | 0.38 |
3. Growth
3.1 Past
The earnings per share for MDP have decreased strongly by -88.89% in the last year.
Looking at the last year, MDP shows a decrease in Revenue. The Revenue has decreased by -0.63% in the last year.
MDP shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 7.82% yearly.
EPS 1Y (TTM)-88.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-317.78%
Revenue 1Y (TTM)-0.63%
Revenue growth 3Y12.2%
Revenue growth 5Y7.82%
Sales Q2Q%-5.94%
3.2 Future
The Earnings Per Share is expected to grow by 53.29% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 10.06% on average over the next years. This is quite good.
EPS Next Y-169.44%
EPS Next 2Y58.9%
EPS Next 3Y77.1%
EPS Next 5Y53.29%
Revenue Next Year-8.08%
Revenue Next 2Y4.36%
Revenue Next 3Y7.5%
Revenue Next 5Y10.06%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 291.00, the valuation of MDP can be described as expensive.
Based on the Price/Earnings ratio, MDP is valued a bit cheaper than 70.00% of the companies in the same industry.
When comparing the Price/Earnings ratio of MDP to the average of the S&P500 Index (26.51), we can say MDP is valued expensively.
The Price/Forward Earnings ratio is 10.52, which indicates a very decent valuation of MDP.
86.67% of the companies in the same industry are more expensive than MDP, based on the Price/Forward Earnings ratio.
MDP is valuated cheaply when we compare the Price/Forward Earnings ratio to 23.13, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 291 | ||
| Fwd PE | 10.52 |
4.2 Price Multiples
MDP's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. MDP is cheaper than 90.00% of the companies in the same industry.
93.33% of the companies in the same industry are more expensive than MDP, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 5.12 | ||
| EV/EBITDA | 5.36 |
4.3 Compensation for Growth
MDP has a very decent profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as MDP's earnings are expected to grow with 77.10% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y58.9%
EPS Next 3Y77.1%
5. Dividend
5.1 Amount
MDP does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
TSX:MDP (12/31/2025, 7:00:00 PM)
2.91
-0.04 (-1.36%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners3.19%
Inst Owner ChangeN/A
Ins Owners7.52%
Ins Owner ChangeN/A
Market Cap94.34M
Revenue(TTM)104.10M
Net Income(TTM)381.00K
Analysts82.22
Price Target6.3 (116.49%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)72.5%
Min EPS beat(2)0.99%
Max EPS beat(2)144%
EPS beat(4)4
Avg EPS beat(4)68.3%
Min EPS beat(4)0.99%
Max EPS beat(4)144%
EPS beat(8)6
Avg EPS beat(8)45.18%
EPS beat(12)9
Avg EPS beat(12)93.03%
EPS beat(16)11
Avg EPS beat(16)69.35%
Revenue beat(2)0
Avg Revenue beat(2)-2.42%
Min Revenue beat(2)-4.22%
Max Revenue beat(2)-0.63%
Revenue beat(4)1
Avg Revenue beat(4)0.38%
Min Revenue beat(4)-4.22%
Max Revenue beat(4)6.82%
Revenue beat(8)2
Avg Revenue beat(8)-2.53%
Revenue beat(12)4
Avg Revenue beat(12)-1.12%
Revenue beat(16)8
Avg Revenue beat(16)1.52%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-500%
EPS NY rev (1m)-340%
EPS NY rev (3m)-340%
Revenue NQ rev (1m)-4.92%
Revenue NQ rev (3m)-4.84%
Revenue NY rev (1m)-2.44%
Revenue NY rev (3m)-2.44%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 291 | ||
| Fwd PE | 10.52 | ||
| P/S | 0.66 | ||
| P/FCF | 5.12 | ||
| P/OCF | 4.24 | ||
| P/B | 1.31 | ||
| P/tB | N/A | ||
| EV/EBITDA | 5.36 |
EPS(TTM)0.01
EY0.34%
EPS(NY)0.28
Fwd EY9.5%
FCF(TTM)0.57
FCFY19.52%
OCF(TTM)0.69
OCFY23.57%
SpS4.4
BVpS2.21
TBVpS-1.05
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0.71
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.25% | ||
| ROE | 0.73% | ||
| ROCE | 8.05% | ||
| ROIC | 5.79% | ||
| ROICexc | 6.63% | ||
| ROICexgc | N/A | ||
| OM | 5.76% | ||
| PM (TTM) | 0.37% | ||
| GM | 53.01% | ||
| FCFM | 12.92% |
ROA(3y)0.64%
ROA(5y)-3.83%
ROE(3y)3.01%
ROE(5y)-32.83%
ROIC(3y)9.89%
ROIC(5y)N/A
ROICexc(3y)12.45%
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)13.73%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.84%
GM growth 5Y-1.43%
F-Score5
Asset Turnover0.7
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 1.57 | ||
| Debt/EBITDA | 0.01 | ||
| Cap/Depr | 30.83% | ||
| Cap/Sales | 2.68% | ||
| Interest Coverage | 1.96 | ||
| Cash Conversion | 107.99% | ||
| Profit Quality | 3530.97% | ||
| Current Ratio | 0.83 | ||
| Quick Ratio | 0.38 | ||
| Altman-Z | 0.58 |
F-Score5
WACC9.12%
ROIC/WACC0.64
Cap/Depr(3y)16.17%
Cap/Depr(5y)70.8%
Cap/Sales(3y)1.03%
Cap/Sales(5y)5.33%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-88.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-317.78%
EPS Next Y-169.44%
EPS Next 2Y58.9%
EPS Next 3Y77.1%
EPS Next 5Y53.29%
Revenue 1Y (TTM)-0.63%
Revenue growth 3Y12.2%
Revenue growth 5Y7.82%
Sales Q2Q%-5.94%
Revenue Next Year-8.08%
Revenue Next 2Y4.36%
Revenue Next 3Y7.5%
Revenue Next 5Y10.06%
EBIT growth 1Y-53.26%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year49.54%
EBIT Next 3Y65.62%
EBIT Next 5Y51.32%
FCF growth 1Y3.54%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y22.81%
OCF growth 3YN/A
OCF growth 5YN/A
MEDEXUS PHARMACEUTICALS INC / MDP.CA FAQ
What is the ChartMill fundamental rating of MEDEXUS PHARMACEUTICALS INC (MDP.CA) stock?
ChartMill assigns a fundamental rating of 5 / 10 to MDP.CA.
What is the valuation status of MEDEXUS PHARMACEUTICALS INC (MDP.CA) stock?
ChartMill assigns a valuation rating of 6 / 10 to MEDEXUS PHARMACEUTICALS INC (MDP.CA). This can be considered as Fairly Valued.
Can you provide the profitability details for MEDEXUS PHARMACEUTICALS INC?
MEDEXUS PHARMACEUTICALS INC (MDP.CA) has a profitability rating of 6 / 10.
What is the financial health of MEDEXUS PHARMACEUTICALS INC (MDP.CA) stock?
The financial health rating of MEDEXUS PHARMACEUTICALS INC (MDP.CA) is 4 / 10.